Sees FY19 revenue $124M-$, consensus $126.18M.
https://thefly.com/landingPageNews.php?id=2872577
Thursday, February 28, 2019
Stericycle sees FY19 EPS $3.32 – $3.72, consensus $4.20
Sees FY19 revenue $3.408B – 3.533B, consensus $3.49B.
https://thefly.com/landingPageNews.php?id=2872595
https://thefly.com/landingPageNews.php?id=2872595
Spectrum sees 2019 SG&A costs down 30% vs. 2018
The company states: “Assuming the previously announced divestiture transaction closes in March, we expect 2019 SG&A costs to decrease by approximately 30% relative to 2018. We expect 2019 R&D costs to increase nominally as reduced spending on the legacy assets is offset by the increased spending on pre-commercial supply and tech transfer activities for ROLONTIS and poziotinib. With the increase of cash from the sale of our commercial assets, we expect our cash balance to be sufficient to fund operations for at least three years.”
https://thefly.com/landingPageNews.php?id=2872599
https://thefly.com/landingPageNews.php?id=2872599
FTC announces settlement with AbbVie over Solvay’s AndroGel
The Federal Trade Commission said it has reached a settlement in the case alleging that the brand-name drug company Solvay and three generic drug companies “illegally” agreed to restrict generic competition to Solvay’s branded testosterone-replacement drug AndroGel for nine years. Under the settlement, Solvay’s current owner AbbVie is prohibited from entering into certain patent infringement settlement agreements that restrict generic entry for certain drugs and contain common forms of reverse payments, the FTC announced. The settlement exempts licenses to enter the market on a later date, compensation for saved future litigation costs up to $7M, a continuation or renewal of a pre-existing agreement, and “several other types of agreements that are unlikely to be anticompetitive,” according to the agency. The order, if approved by the court, will remain in effect for 10 years.
Subscribe to:
Posts (Atom)